Screening large “libraries” of compounds to find those with a desired biological activity is a powerful method for discovering new drugs, but requires a large, expensive and dedicated facility.
Now, scientists at the Florida campus of The Scripps Research Institute (TSRI) have devised the central component of a screening system that would be orders of magnitude smaller and cheaper.
“We’ve developed a device that can do the functional equivalent of high-throughput compound screening on an ultra-miniaturized scale,” said the study’s principal investigator Brian M. Paegel, an associate professor at TSRI.
The advance, published recently online ahead of print in Analytical Chemistry, follows a previous study from the Paegel laboratory in ACS Combinatorial Science that described the synthesis of miniaturized DNA-encoded compound libraries. The new screening device is designed to work with the new type of library.
Current high-throughput screening systems typically occupy 10,000 square feet of space or more and cost millions of dollars. They rely heavily on robotic devices that retrieve compounds from the library, place each compound into a separate small well in an “assay microplate” and measure each compound’s biological activity—for example, whether the compound inhibits a particular enzyme involved in viral replication.
Being almost entirely automated and relatively quick, such systems can rapidly screen the tens or hundreds of thousands of compounds in a typical library. But the great cost of these high-throughput screening systems limits their use to locations at pharmaceutical companies and large research institutions. The Scripps Florida campus houses one of the most active high-throughput screening facilities outside the pharmaceutical industry.
The new approach starts with the use of “one-bead-one-compound” (OBOC) libraries, in which individual compounds are chemically attached to microscopic beads. Over the past two decades, many laboratories have begun to work with OBOC libraries of one type or another, which are so quickly and cheaply prepared and are so compact that such libraries are essentially laboratory consumables.
“It is possible to generate an OBOC library of millions of compounds in a week for about $500,” said Alexander K. Price, a senior research associate in the Paegel laboratory and lead author of the new study.
There are considerable technical challenges involved in putting bead-borne compounds through miniature screening devices. But, as they report in their new paper, Paegel and Price were able to engineer a benchtop-scale device that meets these challenges and can screen OBOC libraries.
The device is built on the microfluidics principles that also underlie inkjet printer technology. Using a “suspension hopper,” which Paegel and Price described in a 2014 Analytical Chemistry paper, the device introduces OBOC library beads into tiny liquid droplets that contain the assay of interest, such as an enzymatic activity assay. The volume of these assay droplets is about 100,000 times less than the volumes used for high-throughput screening assays.
The device then frees each compound from its bead with a photochemical reaction induced by ultraviolet (UV) light and, after an appropriate period of incubation, records the result in each droplet.
Dubbed LIGHTSABR (Light-Induced and Graduated High-Throughput Screening After Bead Release) for its light-based cleavage of compounds from their carrier beads, the device overcomes significant technical hurdles concerning the smooth flow of droplets, the absorption of stray UV irradiation and calibration of the UV waveguide.
A key innovation is that the technique allows users to vary the UV illumination to adjust the amount of a compound cleaved from its bead—and thus adjust the dose of the compound being tested. The team successfully demonstrated this dosing function using an assay designed to find inhibitors of HIV-1 protease, a key enzyme involved in the replication of the virus that causes AIDS.
The next step for Paegel and Price is to apply the microfluidic LIGHTSABR and the laboratory’s DNA-encoded OBOC libraries. “In addition to antiviral compounds, we are also pursuing new antibiotics and other drug classes that address the emergence of resistance in rapidly evolving pathogens,” said Paegel.
“Hundreds of laboratories around the world could operate their own miniaturized screening facilities, using their own assays to go after targets that are of most interest to them,” said Price.
The Latest on: Portable Drug-Discovery System
via Google News
The Latest on: Portable Drug-Discovery System
- Continuous NVP Monitoring and Aseptic Processingon May 19, 2020 at 7:53 am
Deviation from SOPs with regards to configuring/stowing systems before sterile product exposure can be a risk. Some systems have equipment that can be higher than the sterile product throughout ...
- Improve Cleanroom Environmental Monitoring Workflow Efficiencyon May 14, 2020 at 7:36 am
The Simply Paperless system for the MET ONE 3400 series of portable air particle counters is designed to provide confidence in data integrity when employed for environmental monitoring.
- Podcast: A Shift to Modern C++ Programming Modelson May 7, 2020 at 7:23 am
We discuss the important shift to modern C++ programming models, and how the cross-industry oneAPI initiative, and DPC++, bring much-needed portable performance to ... Intel on programming models for ...
- FMI Provides Cloud-Based Drug Discovery Platform Market Projections in its Revised Report, COVID-19 Pandemic Shaping Global Demandon May 6, 2020 at 10:34 am
VALLEY COTTAGE, N.Y. – Drug discovery platform is a place of research and development where medicines are identified for various diseases. Currently, the drug discovery platform is witnessing massive ...
- Laboratory Information Systems Market Size Is Estimated to Reach USD 20757 Million at a 7.1% CAGR By 2025on May 6, 2020 at 6:22 am
The Global Laboratory Information Systems Market size is projected ... can act as a catalyst for the market. The focus on drug discovery & development and development of assays to assess the ...
- COVID-19 Drives CRISPR Diagnosticson May 4, 2020 at 4:14 am
and portable SARS-CoV-2 test using paper strips. The protocol, which relies on company’s SHERLOCK system and incorporates Cas13 and RNA guides that recognize signatures of COVID-19, could ...
- Keith Murphy: “We Believe We are Discovering the Next Step in Drug Development”on April 26, 2020 at 12:43 am
At Viscient, founding partners Miner and Murphy became interested in driving drug discovery in a previously ... and training the immune system the right way,” he went on.
- Secret sauce: the key to serial innovation and profit growthon January 15, 2020 at 3:34 pm
It created the world's first cellular network, and also launched a carphone in 1982 and the first portable mobile phone ... genomic approaches to speed up drug discovery and development.
- Department of Bioengineeringon August 7, 2019 at 11:34 am
and devices and apply them to study basic biological and medical questions that ultimately lead to drug discovery and disease diagnosis. The Biophotonics & Bioimaging Laboratory supports research and ...
- The evolving field of biodefence: therapeutic developments and diagnosticson April 9, 2019 at 6:49 am
There are numerous lead therapeutics that have emerged from drug discovery efforts ... recognition by traditional methods. Robust and portable systems have been proposed for the development ...
via Bing News